TRYPTO Therapeutics

TRYPTO Therapeutics develops a novel class of Tryptophan Hydroxylase inhibitors for serotonin-dependent diseases. The overproduction of peripheral serotonin, catalyzed by the enzyme Tryptophan Hydroxylase 1, leads to the aggravation of many chronic and life-threatening diseases, such as Pulmonary Arterial Hypertension (PAH), Carcinoid Syndrome (CS), colorectal cancer (CRC) and obesity. We have developed and patented a novel class of TPH inhibitors (TPHi) with nanomolar potency in vitro to reduce the pathologically high serotonin synthesis in the periphery. Our new generation of TPHi differs in the scaffold, binding mode, and potency from the two TPHi currently on the market or under clinical investigation.